Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

News SummaryMost relevantAll newsSector newsTweets 

Former Abbott Drug Unit Recalls Synthroid Again

share with twitter share with LinkedIn share with facebook
share via e-mail
01/11/2013 | 09:36pm CEST

Abbott Laboratories' (>> Abbott Laboratories) former pharmaceutical unit, now spun off as AbbVie Inc. (>> AbbVie Inc), recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, marking the second recall of the drug in six months.

One lot of 150-microgram Synthroid tablets was recalled because one bottle was found to contain lower-dose, 75-microgram tablets, AbbVie spokesman Gregory Miley said Friday. The voluntary recall was initiated in early December as a precaution, he said.

The cause was a "manufacturing line clearance error," he said, and AbbVie has taken corrective action. The company isn't aware of any increase in patient complaints or adverse events associated with the label error.

AbbVie was spun off to Abbott shareholders as an independent company at the start of January. AbbVie assumed Synthroid's U.S. marketing rights, though Abbott Labs continues to market the drug outside the U.S.

In July, Abbott recalled three lots of Synthroid because some bottles had defects that could affect the stability of the tablets at the end of shelf life. More than 136,500 bottles of Synthroid were subject to that recall, though Abbott said a majority of them remained under Abbott's control and weren't shipped out.

Both Synthroid recalls were classified by the FDA as Class II, which is typically applied in situations where a product might cause a temporary health problem or pose only a slight threat of a serious health problem.

Synthroid is a synthetic thyroid hormone used by people with hypothyroidism, in which the thyroid gland doesn't produce enough natural thyroid hormone.

Abbott reported $461 million of global Synthroid sales for the first nine months of 2012.

AbbVie shares were recently down a penny at $33.61.

Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, AbbVie Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
06/21 ABBOTT : Hosts Conference Call for Second-Quarter Earnings
06/20 ABBOTT LABORATORIES : Submission of Matters to a Vote of Security Holders (form ..
06/16 ABBOTT LABORATORIES : Broadens Product Offering in Coagulation with Expanded Lau..
06/16 ABBOTT LABORATORIES : Introduces the Alinity hq Hematology Analyzer, the Newest ..
06/15 ABBOTT LABORATORIES : An Application for the Trademark "PRO SCIENCE FINISH" Has ..
06/15 ABBOTT LABORATORIES : Trademark Application for "SIMILAC SENSITIVE" Filed by Abb..
06/15 ABBOTT LABORATORIES : Trademark Application for "ENSURE" Filed by Abbott Laborat..
06/15 ABBOTT LABORATORIES : Trademark Application for "PRO SCIENCE RELOAD" Filed by Ab..
06/15 ABBOTT LABORATORIES : Trademark Application for "PRO SCIENCE" Filed by Abbott La..
06/15 ABBOTT LABORATORIES : ' Trademark Application for "PRO SCIENCE PUSH" Filed
More news
Sector news : Pharmaceuticals - NEC
10:57a Oil keeps a lid on European shares, Novartis drives health stocks
08:48aDJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21 Healthcare stocks rally as Senate set to unveil bill
06/21DJJOHNSON & JOHNSON : J&J Seeking Dismissal of Talc Lawsuits in Missouri
06/21DJR. JOHNSON : Missouri Files Its Own Suit Against Opioid-Painkiller Producers -- ..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/21 Buying Dividend Growth Stocks Without Looking - More Than 2 Years Later
06/16 RISK ARBITRAGE TODAY : What If Rite Aid Deal Doesn't Happen?
06/15 VIG Never Looked So Dividend-y
06/15 STRYKER : Growth At A More Than Reasonable Price
06/14 Top Holdings Of Dividend ETFs (June 2017 Edition)
Financials ($)
Sales 2017 26 375 M
EBIT 2017 5 725 M
Net income 2017 2 939 M
Debt 2017 15 411 M
Yield 2017 2,23%
P/E ratio 2017 31,69
P/E ratio 2018 24,86
EV / Sales 2017 3,78x
EV / Sales 2018 3,52x
Capitalization 84 282 M
More Financials
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 49,0 $
Spread / Average Target 0,81%
Consensus details
EPS Revisions
More Estimates Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON16.50%361 566
ROCHE HOLDING LTD.8.81%224 305
NOVARTIS7.69%214 091
PFIZER4.31%199 854
MERCK AND COMPANY11.19%176 500
More Results